Ticker

Earnings and Valuation This table compares Athersys and Merck KGaA"s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146,000.00 0.00 -$72.53 million ($2.03) N/A Merck KGaA $22.72 billion 0.72 $3.06 billion $6.81 18.52 Merck KGaA has higher revenue and earnings than Athersys. Athersys is

U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, ​according to a Reuters comparison of publicly available prices.

Institutional and Insider Ownership 0.1% of Merck KGaA shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Earnings and Valuation This table compares Calithera Biosciences and

Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript

Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript